- Fund Type: Fund of Funds
- Objective: Region Fund-Euro Countries
- Asset Class: Equity
- Geographic Focus: Euro Countries
Natexis Asset Management Fructifrance Euro
+ Add to WatchlistFRCTFRD:FP
53.94 EUR 0.62 1.16%As of 06:10:00 ET on 06/17/2013.
Snapshot for Natexis Asset Management Fructifrance Euro (FRCTFRD)
| Year To Date: | +5.79% | 3-Month: | +0.45% | 3-Year: | +2.42% | 52-Week Range: | 42.40 - 56.61 |
|---|---|---|---|---|---|---|---|
| 1-Month: | -3.76% | 1-Year: | +26.59% | 5-Year: | -3.52% | Beta vs MXEM: | 1.01 |
Fund Profile & Information for FRCTFRD
Fructifrance Euro is an open-end fund registered in France. The objective of the Fund is to outperform the MSCI EMU Index. The Fund invests the totality of its assets in the master fund (Natixis Actions Euro-ID) which in turn invests at least 90% in equities issued within the euro zone. The Fund invests at least 75% in securities eligible for the PEA.
| Inception Date: | 10-09-1978 | Telephone: | 33-1-78-40-80-00 |
|---|---|---|---|
| Managers: | FREDERIC HARRIAGUE | ||
| Web Site: | www.am.natixis.com | ||
Fundamentals for FRCTFRD
| NAV | (on 2013-06-17) 53.94 |
|---|---|
| Assets (M) | (on 2013-06-17) 295.52 |
| Fund Leveraged | N |
| Minimum Investment | - |
| Minimum Subsequent Investment | - |
Dividends for FRCTFRD
| Dividend Type | Income |
|---|---|
| Dividend Frequency | Annual |
| Last Dividend Net | (on 2013-04-24) 0.72 |
| Dividend Yield (ttm) | 1.33 |
Fees & Expenses for FRCTFRD
| Front Load | 3.00 |
|---|---|
| Back Load | 0.00 |
| Current Mgmt Fee | 0.90 |
| Redemption Fee | 0.00 |
| 12b1 Fee | - |
| Expense Ratio | - |
Top Fund Holdings for FRCTFRD
Filing Date: 03/28/2013| Name | Position | Value | % of Total |
|---|---|---|---|
| Natixis Asset Management Natix | 6,123 | 295,406,153 | 100.050% |
Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
- 1
- 2
- 3
- 4
- 5
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page